Impact of treatment duration on recurrence of chronic pulmonary aspergillosis

Objectives: Limited data exist on the optimal treatment duration for chronic pulmonary aspergillosis (CPA). We investigated the treatment outcome and recurrence rate according to treatment duration in CPA patients. Methods: A total of 196 patients who completed at least 6 months of antifungal therapy (99% oral itraconazole) and achieved favorable treatment responses were analyzed. A Cox's proportional hazards regression model was used to adjust for potential confounding factors in the association between the duration of antifungal therapy (6-12 months vs. >= 12 months) and recurrence. Results: All patients were treated with antifungal agents for at least 6 months (median: 12.5, interquartile range: 8.5-18.4 months) and categorized into 6-12 months group (79/196, 40%) and >= 12 months group (117/196, 60%). The 6-12 months group had significantly higher recurrence rates owing to CPA aggravation after the completion of treatment compared with the >= 12 months group (51% vs. 25%, P = 0.003). In a Cox's proportional hazards regression model, treatment duration >= 12 months was independently associated with a lower risk of recurrence (adjusted hazard ratio: 0.48, 95% confidence interval: 0.28-0.80). Conclusions: Our data suggest that prolonging antifungal therapy beyond 12 months could reduce the recurrence rate in CPA patients. (C) 2021 Published by Elsevier Ltd on behalf of The British Infection Association.

Automated summary

For patients with chronic pulmonary aspergillosis (CPA), extending antifungal therapy beyond 12 months can significantly reduce the recurrence rate.